Available online http://www.academicjournals.org/ajpp
ISSN 1996-0816 ©2010 Academic Journals
Full Length Research Paper
Therapy of Alzheimer’s disease: An update
Prerna Upadhyaya*, Vikas Seth and Mushtaq Ahmad
Department of Pharmacology, Mahatma Gandhi Medical College, Sitapura, Jaipur– 302022, India.
Accepted 23 June, 2010
Alzheimer’s disease is a devastating neurodegenerative disorder manifested by deterioration in memory and cognition, impairment in performing activities of daily living, and many behavioral and neuropsychiatric illnesses. The pathological hallmark of Alzheimer’s disease is widespread neuritic plaques which are accumulations of amyloid beta protein and neurofibrillary tangles. Studies report that deficit in cholinergic system is responsible for cognitive decline and memory loss in patients with
Alzheimer’s disease. Various pharmacologic approaches are developed for the treatment of Alzheimer’s disease. The leading edge therapies of Alzheimer’s disease are approved drugs; Acetylcholinesterase inhibitors and NMDA receptor antagonist. The experimental therapies are mostly disease modifying and have neuroprotective approaches. Gamma secretase inhibitors aim to reduce amyloid beta formation.
Antioxidants, antiinflammatory agents and statins help by preventing oxidation and inflammation.
PPAR gamma agonists, estrogen, heavy metal chelators, 5HT6 antagonists and nicotinic receptor agonists are other therapeutic strategies likely to alter the current treatment paradigm of Alzheimer’s disease. The behavioral abnormalities are best treated first by non-pharmacologic interventions. The pharmacological agents used for treatment of Neuropsychiatric illnesses include antipsychotics, antidepressants and mood stabilizers. Treatment of Alzheimer’s disease also includes health maintenance activities and proper nursing care of the patients.
Key words:
References: Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG (2000) disease. Neurology. 54: 588-93. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al (2003) Avila J, Lucas JJ, P’erez M, Hern’andez (2004). Role of Tau protein in both physiological and pathological conditions Bains J, Birks JS, Dening TD (2007). Antidepressants for treating depression in dementia, Cochrane Database Syst Ballard C, Howard R (2006). Neuroleptic drugs in dementia: benefits and harm, Nat Ballard C, Lana MM, Theodoulou M, et al, Douglas S, McShane R, Jacoby R et al (2008) Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A et al (2005) Birks J, Grimly EJ, Lakovidou V, Tsolaki M, Holt FE (2009). Rivasigmine for Alzheimer disease Birks J, Harvey RJ (2006). Donepezil for dementia due to Alzheimer disease Braak H, Braak E (1994). Pathology of Alzheimer’s disease. In: Calne D, ed McCormick WC, et al(1994). Postmenopausal estrogen replacement therapy and the risk of Alzheimer 's disease: A population-based Brinton RD (2004). Impact of estrogen therapy on Alzheimer 's disease: a fork in the road? CNS Drugs Brion JP (1998). Neurofibrillary tangles and Alzheimer’s disease. Eur. Burns A, Murphy D. (1996). Protection against Alzheimer 's disease? [Commentary] Bush AI, Pettingell WH, Paradis MD, and Tanze RE (1994). Modulation of a beta adhesiveness and secretase site cleavage by zinc Camps P. Munoz-Torrero D (2002). Cholinergic drugs in pharmacotherapy of Alzheimer 's disease Chandra V, Bharucha NE, Schoenberg BS (1986). Conditions associated with Alzheimer’s disease at death: case-control study. Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, Dekosky ST (1998)